DNA vaccination and gene therapy: optimization and delivery for cancer therapy

被引:39
作者
Bodles-Brakhop, Angela M. [1 ]
Draghia-Akli, Ruxandra [1 ]
机构
[1] VGX Pharmaceut Inc, The Woodlands, TX 77381 USA
关键词
cancer; DNA vaccine; electroporation; immune therapy; plasmid;
D O I
10.1586/14760584.7.7.1085
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This review will focus on DNA vaccine approaches for the prevention or treatment of cancer and its complications. DNA vaccine therapies are a relatively novel method of cancer treatment with the goal to induce immunity against tumor-associated antigens. Both viral and nonviral vaccines have been tested in preclinical and clinical models with variable success. However, the development of new delivery methods, such as electroporation, as well as the use of agents that improve antigen uptake or presentation, and the optimization of the transgene sequences, are overcoming historical drawbacks, Efficacy and safety issues of the in vivo use of DNA-based vaccines, as well as data from preclinical and recent clinical studies, are discussed. Novel developments will improve clinical efficacy, with the potential for DNA vaccination to enter in to the arsenal of cancer therapies in the near future.
引用
收藏
页码:1085 / 1101
页数:17
相关论文
共 113 条
[61]   Toxicity of cationic lipids and cationic polymers in gene delivery [J].
Lv, Hongtao ;
Zhang, Shubiao ;
Wang, Bing ;
Cui, Shaohui ;
Yan, Jie .
JOURNAL OF CONTROLLED RELEASE, 2006, 114 (01) :100-109
[62]   Water insoluble and soluble lipids for gene delivery [J].
Mahato, RI .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (05) :699-712
[63]   Ultrasound facilitates transduction of naked plasmid DNA into colon carcinoma cells in vitro and in vivo [J].
Manome, Y ;
Nakamura, M ;
Ohno, T ;
Furuhata, H .
HUMAN GENE THERAPY, 2000, 11 (11) :1521-1528
[64]   Tumour immunity: effector response to tumour and role of the microenvironment [J].
Mantovani, Alberto ;
Romero, Pedro ;
Palucka, A. Karolina ;
Marincola, Francesco M. .
LANCET, 2008, 371 (9614) :771-783
[65]   Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine [J].
Marshall, DJ ;
Rudnick, KA ;
McCarthy, SG ;
San Mateo, LR ;
Harris, MC ;
McCauley, C ;
Snyder, LA .
VACCINE, 2006, 24 (03) :244-253
[66]   Carcinoembryonic antigen-based vaccines [J].
Marshall, J .
SEMINARS IN ONCOLOGY, 2003, 30 (03) :30-36
[67]   The role of CpG in DNA vaccines [J].
McCluskie, MJ ;
Weeratna, RD ;
Davis, HL .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2000, 22 (1-2) :125-132
[68]   The effect of the histological properties of tumors on transfection efficiency of electrically assisted gene delivery to solid tumors in mice [J].
Mesojednik, S. ;
Pavlin, D. ;
Sersa, G. ;
Coer, A. ;
Kranjc, S. ;
Grosel, A. ;
Tevz, G. ;
Cemazar, M. .
GENE THERAPY, 2007, 14 (17) :1261-1269
[69]   DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice [J].
Mkrtichyan, M. ;
Ghochikyan, A. ;
Loukinov, D. ;
Davtyan, H. ;
Ichim, T. E. ;
Cribbs, D. H. ;
Lobanenkov, V. V. ;
Agadjanyan, M. G. .
GENE THERAPY, 2008, 15 (01) :61-64
[70]   CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy [J].
Murad, Yanal M. ;
Clay, Timothy M. ;
Lyerly, H. Kim ;
Morse, Michael A. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (08) :1257-1266